1. MARKETS
  2. SECTOR : PHARMA & BIOTECH
  3. INDUSTRY : MAJOR PHARMACEUTICALS
  4. PUMA BIOTECHNOLOGY INC
Puma Biotechnology Inc
XNAS: PBYI
9.600.08(0.84%)
327.1K
XNAS Volume

XNAS 18 Sep, 2026 5:30 PM (EDT)

Portfolio

Alert

My Notes

Puma biotech Inc quarterly and annual earnings report: results, revenue, profit, P&L, balance sheet, cash flow, financial ratios, revenue mix, peer comparison, and financial documents

View Charts

Forecaster Analyst Estimates for Puma biotech Inc share price target, revenues, EPS, net income and more

Puma biotech Inc quarterly results: revenue, profit, and P&L – 13 quarter history

  • POSITIVE

    Quarterly Revenue Puma biotech Inc Jun-2026 Quarterly Revenue is $57 Million which is growth of 7.8% YoY.

  • POSITIVE

    Quarterly Net Profit Puma biotech Inc Jun-2026 Quarterly Net Profit is $8 Million which is growth of 39.9% YoY.

Puma Biotechnology Inc, Earnings Report - Quarterly Results, standalone, All financials are in USD Million and price data in USD
IndicatorGraphJun '26Mar '26Dec '25Sep '25Jun '25Mar '25Dec '24Sep '24Jun '24Mar '24Dec '23Sep '23Jun '23
Operating Rev.
56.544.875.554.552.44659.180.547.143.872.256.154.6
Cost Of Rev.
12.510.423.112.212.310.613.929.110.710.724.313.311.9
Gross Profit
4434.452.342.340.135.545.251.536.43347.942.842.7
36.438.235.232.733.531.531.829.438.635.333.133.637.8
Operating Profit
7.6-3.817.19.66.6413.422.1-2.2-2.314.89.24.9
0.70.3-0.1-0.5-0.9-1.1-1.4-1.8-2.1-2.4-2.6-2.7-2.7
Profit Before Tax
8.2-3.417.19.26.23.312.220.6-4.2-4.612.862.3
Tax
0.10.33.70.40.30.3-7.10.30.40.20.50.20.2
8.2-3.813.48.85.9319.320.3-4.5-4.812.35.82.1
Diluted NI Avail to Com Stockholders Ann.
8.2-3.813.48.85.9319.320.3-4.5-4.812.35.82.1
Basic EPS
0.2-0.10.30.20.10.10.40.4-0.1-0.10.30.10.1
Diluted EPS After ExtraOrdinary
0.2-0.10.30.20.10.10.40.4-0.1-0.10.30.10.1
Number Of Shares End
50.950.950.450.349.749.649.14948.348.247.647.546.8
Net Income Continuing Discontinued Operations
8.2-3.813.48.85.9319.320.3-4.5-4.812.35.82.1
Normalized Income
8.2-3.813.48.85.9319.320.3-4.5-4.812.36.42.1
Interest Income
0.811111.11.21.31.210.70.70.7
Interest
0.20.71.11.51.82.22.63.13.43.43.43.33.3
Net Interest Income
0.70.3-0.1-0.5-0.9-1.1-1.4-1.8-2.1-2.4-2.6-2.7-2.7
EBIT
8.4-2.718.210.785.414.923.7-0.8-1.216.29.45.6
EBITDA
10.9-0.120.913.510.88.217.726.62.11.719.112.28.5
Reconciled Cost Of Rev.
12.510.423.112.212.310.613.929.110.710.724.313.311.9
Reconciled Depr.
2.52.62.72.72.82.82.82.92.92.92.92.92.9
Profit From Continuing Operations
8.2-3.813.48.85.9319.320.3-4.5-4.812.35.82.1
Normalized EBITDA
10.9-0.120.913.510.88.217.726.62.11.719.112.98.5
*All financials are in USD Million and price data in USD

Puma biotech Inc competitor comparison and performance snapshot within industry

Puma biotech Inc annual results: revenue, profit, P&L, and margins as of Dec 2025 – 11 year history

  • NEGATIVE

    Annual Revenue Puma biotech Inc Dec-2025 Annual Revenue is $228 Million which is growth of -0.9% YoY.

  • POSITIVE

    Annual Net Profit Puma biotech Inc Dec-2025 Annual Net Profit is $31 Million which is growth of 2.8% YoY.

Puma Biotechnology Inc, Earnings Report - Annual Results, standalone, All financials are in USD Million and price data in USD
IndicatorGraphCAGR 3 YrsCAGR 5 YrsTTMDec '25Dec '24Dec '23Dec '22Dec '21Dec '20Dec '19Dec '18Dec '17Dec '16Dec '15
0.1%
0.3%
 228.4230.5235.6228253.2225.1272.325127.7
Cost Of Rev. Ann.
1.8%
8.1%
58.258.264.462.755.163.739.436.834.65.6--
Gross Profit Ann.
-0.5%
-1.7%
173170.2166.1173172.9189.5185.7235.4216.422.1--
Operating Exp. Ann.
-2.2%
-9.3%
142.6132.9135.1139.7142.2188.2216.1273.4311314.5276.6240.3
Operating Profit Ann.
6.7%
-
30.437.33133.330.71.3-30.4-37.9-94.7-292.4-276.6-240.3
-
-
0.3-2.5-7.7-10.7-10.8-12.7-13.6-12.2-9.20.511
Other Exp. Ann.
-
-
 10.90.1-19.5-17.4-15.8-25.5-9.7-0.1-0.40
PBT Ann.
315.2%
-
31.235.824.122.70.5-28.8-59.8-75.6-113.6-292-276-239.3
Tax Ann.
111%
88%
4.54.7-6.21.10.50.30.2-----
-
-
26.731.130.321.6-29.1-60-75.6-113.6-292-276-239.3
Diluted NI Avail to Com Stockholders Ann.
-
-
26.731.130.321.6-29.1-60-75.6-113.6-292-276-239.3
EPS Ann.
-
-
 0.60.60.5-0.7-1.5-2-3-7.9-8.3-7.5
Diluted EPS Ann.
-
-
 0.60.60.5-0.7-1.5-2-3-7.9-8.3-7.5
Number Of Shares End
3.2%
4.8%
 50.449.147.645.84139.939.138.237.535.732.5
Total Exp. Ann.
-1.1%
-5.6%
 191.1199.5202.4197.3251.9255.5310.2345.7320.1276.6240.3
Net Income Continuing Discontinued Operations Ann.
-
-
26.731.130.321.6-29.1-60-75.6-113.6-292-276-239.3
Normalized Income Ann.
26.4%
-
26.731.130.322.215.4-16.2-48.2-50-104.6-292-276-239.3
Interest Income Ann.
72.4%
52.3%
3.94.14.72.60.80.20.52.91.81.311
Interest Ann.
-17.1%
-14.1%
3.56.612.513.311.612.814.115110.7--
EBITDA Ann.
36.4%
-
45.253.348.147.521-5.4-35.7-52.5-95.2-288.4-275.5-239.5
Reconciled Cost Of Rev. Ann.
1.8%
8.1%
58.258.264.462.755.163.739.436.834.65.6--
Reconciled Depr. Ann.
7%
1.7%
10.510.911.511.58.910.6108.17.42.81.20.8
Profit From Continuing Operations Ann.
-
-
26.731.130.321.6-29.1-60-75.6-113.6-292-276-239.3
Normalized EBITDA Ann.
9.7%
-
45.253.348.148.240.412.3-19.5-26.9-86.2-288.4-275.5-239.5
*All financials are in USD Million and price data in USD
Total Rev. Ann.
1Y CHG
-0.9%
2Y CAGR
-1.5%
3Y CAGR
0.1%
5Y CAGR
0.3%
7Y CAGR
-1.3%
Total Revenue Annual is falling faster than historical averages.
Net Profit Ann.
1Y CHG
2.6%
2Y CAGR
20%
Net Profit Annual growth is lower than historical averages.
Operating Exp. Ann.
1Y CHG
-1.6%
2Y CAGR
-2.5%
3Y CAGR
-2.2%
5Y CAGR
-9.3%
7Y CAGR
-11.4%
10Y CAGR
-5.8%
Operating Expenses Annual Cr is falling slower than historical averages.

Puma biotech Inc balance sheet as of Dec 2025: assets, liabilities, reserves, and borrowings – 11 year history

  • POSITIVE

    Total Shareholders Fund Puma biotech Inc Dec-2025 Total Shareholders Fund is $130 Million which is growth of 41.5% YoY.

  • POSITIVE

    Total Assets Puma biotech Inc Dec-2025 Total Assets is $216 Million which is growth of 1.4% YoY.

Puma Biotechnology Inc, Balance Sheet, standalone, All financials are in USD Million and price data in USD
IndicatorGraphCAGR 3 YrsCAGR 5 YrsDec '25Dec '24Dec '23Dec '22Dec '21Dec '20Dec '19Dec '18Dec '17Dec '16Dec '15
-0.9%
-2.4%
216.3213.3230.5222.1226.6244.2234.9259.1165.5252.8239.8
-24.6%
-19.2%
86121.2177.1200.5229250.2217.4224.8112.24333.8
82%
-
130.392.153.421.6-2.5-617.534.353.3209.8206
Total Capitalization Ann.
2.8%
10.8%
130.3113.8119.1119.994.778.1112.4186.2101.8209.8206
Tangible Assets Ann.
-
-
8941-7.4-49-68.6-80.1-23-10.15209.8206
Working Capital Ann.
12.7%
20.6%
81.451.656.856.830.431.975.5135.948.1199191.1
Invested Capital Ann.
8.4%
10.6%
152.9159.2153.1119.994.792.4112.4186.2101.8209.8206
Tangible Book Value Ann.
-
-
8941-7.4-49-68.6-80.1-23-10.15209.8206
Borrowings Ann.
-37%
-25.1%
28.674.1111.5114.3116.6121120.2151.948.5--
Net Debt Ann.
-
-
--15.122.1341334.943.5---
Share Issued Ann.
2.8%
4.7%
50.449.147.746.441.240.139.238.337.636.832.5
Number Of Shares End
3.2%
4.8%
50.449.147.645.84139.939.138.237.535.732.5
*All financials are in USD Million and price data in USD
Total Assets Ann.
1Y CHG
1.4%
2Y CAGR
-3.1%
3Y CAGR
-0.9%
5Y CAGR
-2.4%
7Y CAGR
-2.5%
10Y CAGR
-1%
Total Assets Annual growth is higher than historical averages.
Total Current Liabilities Ann.
1Y CHG
-15.4%
2Y CAGR
-9.6%
3Y CAGR
1.6%
5Y CAGR
-6.6%
7Y CAGR
2.8%
10Y CAGR
9.6%
Total Current Liabilities Annual Cr is falling faster than historical averages.
Total ShareHolders Funds Ann.
1Y CHG
41.5%
2Y CAGR
56.2%
3Y CAGR
82%
7Y CAGR
21%
10Y CAGR
-4.5%
Total ShareHolders Funds Annual growth is stable compared to historical averages.

Puma biotech Inc ROE, ROCE, book value, and debt-to-equity ratio as of Dec 2025 – 11 year history

  • POSITIVE

    Book Value Per Share Puma biotech Inc Book Value Per Share is $3 which is growth of 29.1% YoY.

  • NEUTRAL

    ROE Puma biotech Inc ROE is 0% which is growth of 0% YoY.

Puma Biotechnology Inc, Ratios, standalone, All financials are in USD Million and price data in USD
IndicatorGraphCAGR 3 YrsCAGR 5 YrsDec '25Dec '24Dec '23Dec '22Dec '21Dec '20Dec '19Dec '18Dec '17Dec '16Dec '15
RoA Ann. %
-
-
-13.64%9.54%-12.37%-25.04%-30.60%-53.49%-139.59%-112.06%-118.87%
ROE Ann. %
-
-
-41.60%57.54%0.02%--1,042.30%-292.05%-259.28%-221.91%-132.75%-148.14%
ROIC %
-
-
-12.69.4-2.5---6.3-15.6-56.1-48.4-27.5
OPM Ann. %
6.6%
-
16.33%13.44%14.12%13.47%0.51%-13.51%-13.93%-37.72%-1,056.13%--
Inventory Turnover Ratio Ann.
-
-
-8.210.89.512.111.912.714.92.8--
Asset Turnover Ann. %
-
-
-1111.10.91.11.20.1--
Working Capital Turnover Ann.
-11.2%
-17%
2.84.54.248.37.13.61.90.6
Quick Ratio Ann.
-
-
-1.41.51.61.111.62.81.66.16.7
Current Ratio Ann.
-
-
-1.51.61.71.31.31.831.86.36.9
Interest Coverage Ratio Ann.
-
-
-2.92.71-1.3-3.3-4-9.3-404.5--
LT Debt To Equity Ann.
-
-
-0.31.45.1--6.74.40.9--
*All financials are in USD Million and price data in USD

Puma biotech Inc cash flow: net, operating, investing, and financing flows as of Dec 2025 – 11 year history

  • POSITIVE

    Cash From Operating Activity Puma biotech Inc Dec-2025 Cash From Operating Activity is $42 Million which is growth of 7.4% YoY.

  • NEGATIVE

    Net Cash Flow Puma biotech Inc Dec-2025 Net Cash Flow is $-40 Million which is growth of -157.6% YoY.

Puma Biotechnology Inc, Cash Flow, standalone, All financials are in USD Million and price data in USD
IndicatorGraphCAGR 3 YrsCAGR 5 YrsDec '25Dec '24Dec '23Dec '22Dec '21Dec '20Dec '19Dec '18Dec '17Dec '16Dec '15
-
120.6%
41.838.927-15.820.70.822.4-24.1-172.5-141.7-154.5
-
-
-36.2-20.4-19.17.1-10.923.45.2-57.6-15.4142.2-85.9
-
-
-45.2-33.912.2-31.90.1-67.1108.575.1162.4233.4
Cash Plus Cash Eqv. End Of Year Ann.
-26.2%
-20.1%
31.771.386.778.875.397.573.2112.781.7194.531.6
Net Increase In Cash Plus Cash Eqv.s Ann.
-
-
-39.6-15.47.93.5-22.224.2-39.526.7-112.8162.9-7
Cash Plus Cash Eqv. Begin Of Year Ann.
-1.8%
-0.5%
71.386.778.875.397.573.2112.786194.531.638.5
Income Tax Paid Supplemental Data Ann.
55.4%
49.6%
1.51.20.70.40.30.2-----
Interest Paid Supplemental Data Ann.
-17.4%
-9.8%
5.810.811.610.310.39.711.78.10.3--
Capex Ann.
-
-
-0.1-0.1-12.6-7--20.1-0.3-0.6-50.4-7.3-1.2
Issuance Of Capital Stock Ann.
-
-
-12.5---161.9205.1
Issuance Of Debt Ann.
-
-
--98.58.42510550--
Repayment Of Debt Ann.
-
-
-44.4-33.3-100-8.4-80----
Repurchase Of Capital Stock Ann.
-
-
-----------
Free Cash Flow Ann.
-
-
41.738.914.4-22.820.7-19.322.1-24.7-222.9-149-155.7
*All financials are in USD Million and price data in USD
Cash from Operating Act. Ann.
1Y CHG
7.5%
2Y CAGR
24.4%
5Y CAGR
120.6%
Cash from Operating Activity Annual growth is lower than historical averages.